Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer

Polymorphisms in DNA repair pathways may play a relevant role in lung cancer survival in never-smokers. Furthermore, they could be implicated in the response to chemotherapy and toxicity of platinum agents. The aim of this study was to evaluate the influence of various genetic polymorphisms in the B...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2020-12, Vol.10 (1), p.21147-21147, Article 21147
Main Authors: Casal-Mouriño, Ana, Ruano-Ravina, Alberto, Torres-Durán, María, Parente-Lamelas, Isaura, Provencio-Pulla, Mariano, Castro-Añón, Olalla, Vidal-García, Iria, Abal-Arca, José, Piñeiro-Lamas, María, Fernández-Villar, Alberto, Valdés-Cuadrado, Luis, Barros-Dios, Juan Miguel, Pérez-Ríos, Mónica
Format: Article
Language:English
Subjects:
692/4028
692/699
Adenocarcinoma
Aged
Case-Control Studies
Chemotherapy
Deoxyribonucleic acid
DNA
DNA Repair
ERCC1 protein
Female
Gene polymorphism
Humanities and Social Sciences
Humans
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Male
Middle Aged
multidisciplinary
Non-Smokers
OGG1 protein
Platinum
Polymorphism, Single Nucleotide
Radiation therapy
Science
Science (multidisciplinary)
Survival
Survival Analysis
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c474t-2bf7c1509507248581285d1919bee60f2c6e80a792bfd4d025b8ff8d130d82a03
cites cdi_FETCH-LOGICAL-c474t-2bf7c1509507248581285d1919bee60f2c6e80a792bfd4d025b8ff8d130d82a03
container_end_page 21147
container_issue 1
container_start_page 21147
container_title Scientific reports
container_volume 10
creator Casal-Mouriño, Ana
Ruano-Ravina, Alberto
Torres-Durán, María
Parente-Lamelas, Isaura
Provencio-Pulla, Mariano
Castro-Añón, Olalla
Vidal-García, Iria
Abal-Arca, José
Piñeiro-Lamas, María
Fernández-Villar, Alberto
Valdés-Cuadrado, Luis
Barros-Dios, Juan Miguel
Pérez-Ríos, Mónica
description Polymorphisms in DNA repair pathways may play a relevant role in lung cancer survival in never-smokers. Furthermore, they could be implicated in the response to chemotherapy and toxicity of platinum agents. The aim of this study was to evaluate the influence of various genetic polymorphisms in the BER and NER DNA repair pathways on survival and toxicity in never-smoker LC patients. The study included never-smokers LC cases diagnosed from 2011 through 2019, belonging to the Lung Cancer Research In Never Smokers study. A total of 356 never-smokers cases participated (79% women; 83% adenocarcinoma and 65% stage IV). Survival at 3 and 5 years from diagnosis was not associated with genetic polymorphisms, except in the subgroup of patients who received radiotherapy or chemo-radiotherapy, and presented with ERCC1 rs3212986 polymorphism. There was greater toxicity in those presenting OGG1 rs1052133 (CG) and ERCC1 rs11615 polymorphisms among patients treated with radiotherapy or chemo-radiotherapy, respectively. In general, polymorphisms in the BER and NER pathways do not seem to play a relevant role in survival and response to treatment among never-smoker LC patients.
doi_str_mv 10.1038/s41598-020-78051-5
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7713126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473283867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-2bf7c1509507248581285d1919bee60f2c6e80a792bfd4d025b8ff8d130d82a03</originalsourceid><addsrcrecordid>eNp9kUFP3DAQhS3UqiDKH-gBWeqll1B7HMfOpVJBlFZCBaH2bHkdZ2Oa2IudLOy_r5dQChzwZSy_b9549BD6QMkRJUx-TiXltSwIkEJIwmnBd9AekJIXwADePLnvooOUrkk-HOqS1u_QLmMgGK9gD91dhn4zhLjqXBoSdh6PncXHp1dY-wb_zHWlx-5Wb9L9QxZdzFTbT9Ybi4PHaYprt9b9rIc7Z9y42Rp5u7axSEP4Y2PCt27scD_5JTY6d8b36G2r-2QPHuo--v3t9NfJ9-L84uzHydfzwpSiHAtYtMJQTmpOBJSSSwqSN7Sm9cLairRgKiuJFnUGm7IhwBeybWVDGWkkaML20ZfZdzUtBtsY68eoe7WKbtBxo4J26rniXaeWYa2EoIxClQ0-PRjEcDPZNKrBJWP7XnsbpqSgrEQFhMF21scX6HWYos_rZUowkExWIlMwUyaGlKJtHz9Didpmq-ZsVc5W3WereG46fLrGY8u_JDPAZiBlyS9t_D_7Fdu_3MOwFg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473283867</pqid></control><display><type>article</type><title>Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Casal-Mouriño, Ana ; Ruano-Ravina, Alberto ; Torres-Durán, María ; Parente-Lamelas, Isaura ; Provencio-Pulla, Mariano ; Castro-Añón, Olalla ; Vidal-García, Iria ; Abal-Arca, José ; Piñeiro-Lamas, María ; Fernández-Villar, Alberto ; Valdés-Cuadrado, Luis ; Barros-Dios, Juan Miguel ; Pérez-Ríos, Mónica</creator><creatorcontrib>Casal-Mouriño, Ana ; Ruano-Ravina, Alberto ; Torres-Durán, María ; Parente-Lamelas, Isaura ; Provencio-Pulla, Mariano ; Castro-Añón, Olalla ; Vidal-García, Iria ; Abal-Arca, José ; Piñeiro-Lamas, María ; Fernández-Villar, Alberto ; Valdés-Cuadrado, Luis ; Barros-Dios, Juan Miguel ; Pérez-Ríos, Mónica</creatorcontrib><description>Polymorphisms in DNA repair pathways may play a relevant role in lung cancer survival in never-smokers. Furthermore, they could be implicated in the response to chemotherapy and toxicity of platinum agents. The aim of this study was to evaluate the influence of various genetic polymorphisms in the BER and NER DNA repair pathways on survival and toxicity in never-smoker LC patients. The study included never-smokers LC cases diagnosed from 2011 through 2019, belonging to the Lung Cancer Research In Never Smokers study. A total of 356 never-smokers cases participated (79% women; 83% adenocarcinoma and 65% stage IV). Survival at 3 and 5 years from diagnosis was not associated with genetic polymorphisms, except in the subgroup of patients who received radiotherapy or chemo-radiotherapy, and presented with ERCC1 rs3212986 polymorphism. There was greater toxicity in those presenting OGG1 rs1052133 (CG) and ERCC1 rs11615 polymorphisms among patients treated with radiotherapy or chemo-radiotherapy, respectively. In general, polymorphisms in the BER and NER pathways do not seem to play a relevant role in survival and response to treatment among never-smoker LC patients.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-78051-5</identifier><identifier>PMID: 33273562</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4028 ; 692/699 ; Adenocarcinoma ; Aged ; Case-Control Studies ; Chemotherapy ; Deoxyribonucleic acid ; DNA ; DNA Repair ; ERCC1 protein ; Female ; Gene polymorphism ; Humanities and Social Sciences ; Humans ; Lung cancer ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Male ; Middle Aged ; multidisciplinary ; Non-Smokers ; OGG1 protein ; Platinum ; Polymorphism, Single Nucleotide ; Radiation therapy ; Science ; Science (multidisciplinary) ; Survival ; Survival Analysis ; Toxicity</subject><ispartof>Scientific reports, 2020-12, Vol.10 (1), p.21147-21147, Article 21147</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-2bf7c1509507248581285d1919bee60f2c6e80a792bfd4d025b8ff8d130d82a03</citedby><cites>FETCH-LOGICAL-c474t-2bf7c1509507248581285d1919bee60f2c6e80a792bfd4d025b8ff8d130d82a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2473283867/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2473283867?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,36992,44569,53769,53771,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33273562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Casal-Mouriño, Ana</creatorcontrib><creatorcontrib>Ruano-Ravina, Alberto</creatorcontrib><creatorcontrib>Torres-Durán, María</creatorcontrib><creatorcontrib>Parente-Lamelas, Isaura</creatorcontrib><creatorcontrib>Provencio-Pulla, Mariano</creatorcontrib><creatorcontrib>Castro-Añón, Olalla</creatorcontrib><creatorcontrib>Vidal-García, Iria</creatorcontrib><creatorcontrib>Abal-Arca, José</creatorcontrib><creatorcontrib>Piñeiro-Lamas, María</creatorcontrib><creatorcontrib>Fernández-Villar, Alberto</creatorcontrib><creatorcontrib>Valdés-Cuadrado, Luis</creatorcontrib><creatorcontrib>Barros-Dios, Juan Miguel</creatorcontrib><creatorcontrib>Pérez-Ríos, Mónica</creatorcontrib><title>Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Polymorphisms in DNA repair pathways may play a relevant role in lung cancer survival in never-smokers. Furthermore, they could be implicated in the response to chemotherapy and toxicity of platinum agents. The aim of this study was to evaluate the influence of various genetic polymorphisms in the BER and NER DNA repair pathways on survival and toxicity in never-smoker LC patients. The study included never-smokers LC cases diagnosed from 2011 through 2019, belonging to the Lung Cancer Research In Never Smokers study. A total of 356 never-smokers cases participated (79% women; 83% adenocarcinoma and 65% stage IV). Survival at 3 and 5 years from diagnosis was not associated with genetic polymorphisms, except in the subgroup of patients who received radiotherapy or chemo-radiotherapy, and presented with ERCC1 rs3212986 polymorphism. There was greater toxicity in those presenting OGG1 rs1052133 (CG) and ERCC1 rs11615 polymorphisms among patients treated with radiotherapy or chemo-radiotherapy, respectively. In general, polymorphisms in the BER and NER pathways do not seem to play a relevant role in survival and response to treatment among never-smoker LC patients.</description><subject>692/4028</subject><subject>692/699</subject><subject>Adenocarcinoma</subject><subject>Aged</subject><subject>Case-Control Studies</subject><subject>Chemotherapy</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA Repair</subject><subject>ERCC1 protein</subject><subject>Female</subject><subject>Gene polymorphism</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Non-Smokers</subject><subject>OGG1 protein</subject><subject>Platinum</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Radiation therapy</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Toxicity</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kUFP3DAQhS3UqiDKH-gBWeqll1B7HMfOpVJBlFZCBaH2bHkdZ2Oa2IudLOy_r5dQChzwZSy_b9549BD6QMkRJUx-TiXltSwIkEJIwmnBd9AekJIXwADePLnvooOUrkk-HOqS1u_QLmMgGK9gD91dhn4zhLjqXBoSdh6PncXHp1dY-wb_zHWlx-5Wb9L9QxZdzFTbT9Ybi4PHaYprt9b9rIc7Z9y42Rp5u7axSEP4Y2PCt27scD_5JTY6d8b36G2r-2QPHuo--v3t9NfJ9-L84uzHydfzwpSiHAtYtMJQTmpOBJSSSwqSN7Sm9cLairRgKiuJFnUGm7IhwBeybWVDGWkkaML20ZfZdzUtBtsY68eoe7WKbtBxo4J26rniXaeWYa2EoIxClQ0-PRjEcDPZNKrBJWP7XnsbpqSgrEQFhMF21scX6HWYos_rZUowkExWIlMwUyaGlKJtHz9Didpmq-ZsVc5W3WereG46fLrGY8u_JDPAZiBlyS9t_D_7Fdu_3MOwFg</recordid><startdate>20201203</startdate><enddate>20201203</enddate><creator>Casal-Mouriño, Ana</creator><creator>Ruano-Ravina, Alberto</creator><creator>Torres-Durán, María</creator><creator>Parente-Lamelas, Isaura</creator><creator>Provencio-Pulla, Mariano</creator><creator>Castro-Añón, Olalla</creator><creator>Vidal-García, Iria</creator><creator>Abal-Arca, José</creator><creator>Piñeiro-Lamas, María</creator><creator>Fernández-Villar, Alberto</creator><creator>Valdés-Cuadrado, Luis</creator><creator>Barros-Dios, Juan Miguel</creator><creator>Pérez-Ríos, Mónica</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201203</creationdate><title>Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer</title><author>Casal-Mouriño, Ana ; Ruano-Ravina, Alberto ; Torres-Durán, María ; Parente-Lamelas, Isaura ; Provencio-Pulla, Mariano ; Castro-Añón, Olalla ; Vidal-García, Iria ; Abal-Arca, José ; Piñeiro-Lamas, María ; Fernández-Villar, Alberto ; Valdés-Cuadrado, Luis ; Barros-Dios, Juan Miguel ; Pérez-Ríos, Mónica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-2bf7c1509507248581285d1919bee60f2c6e80a792bfd4d025b8ff8d130d82a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/4028</topic><topic>692/699</topic><topic>Adenocarcinoma</topic><topic>Aged</topic><topic>Case-Control Studies</topic><topic>Chemotherapy</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA Repair</topic><topic>ERCC1 protein</topic><topic>Female</topic><topic>Gene polymorphism</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Non-Smokers</topic><topic>OGG1 protein</topic><topic>Platinum</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Radiation therapy</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Casal-Mouriño, Ana</creatorcontrib><creatorcontrib>Ruano-Ravina, Alberto</creatorcontrib><creatorcontrib>Torres-Durán, María</creatorcontrib><creatorcontrib>Parente-Lamelas, Isaura</creatorcontrib><creatorcontrib>Provencio-Pulla, Mariano</creatorcontrib><creatorcontrib>Castro-Añón, Olalla</creatorcontrib><creatorcontrib>Vidal-García, Iria</creatorcontrib><creatorcontrib>Abal-Arca, José</creatorcontrib><creatorcontrib>Piñeiro-Lamas, María</creatorcontrib><creatorcontrib>Fernández-Villar, Alberto</creatorcontrib><creatorcontrib>Valdés-Cuadrado, Luis</creatorcontrib><creatorcontrib>Barros-Dios, Juan Miguel</creatorcontrib><creatorcontrib>Pérez-Ríos, Mónica</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Casal-Mouriño, Ana</au><au>Ruano-Ravina, Alberto</au><au>Torres-Durán, María</au><au>Parente-Lamelas, Isaura</au><au>Provencio-Pulla, Mariano</au><au>Castro-Añón, Olalla</au><au>Vidal-García, Iria</au><au>Abal-Arca, José</au><au>Piñeiro-Lamas, María</au><au>Fernández-Villar, Alberto</au><au>Valdés-Cuadrado, Luis</au><au>Barros-Dios, Juan Miguel</au><au>Pérez-Ríos, Mónica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-12-03</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>21147</spage><epage>21147</epage><pages>21147-21147</pages><artnum>21147</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Polymorphisms in DNA repair pathways may play a relevant role in lung cancer survival in never-smokers. Furthermore, they could be implicated in the response to chemotherapy and toxicity of platinum agents. The aim of this study was to evaluate the influence of various genetic polymorphisms in the BER and NER DNA repair pathways on survival and toxicity in never-smoker LC patients. The study included never-smokers LC cases diagnosed from 2011 through 2019, belonging to the Lung Cancer Research In Never Smokers study. A total of 356 never-smokers cases participated (79% women; 83% adenocarcinoma and 65% stage IV). Survival at 3 and 5 years from diagnosis was not associated with genetic polymorphisms, except in the subgroup of patients who received radiotherapy or chemo-radiotherapy, and presented with ERCC1 rs3212986 polymorphism. There was greater toxicity in those presenting OGG1 rs1052133 (CG) and ERCC1 rs11615 polymorphisms among patients treated with radiotherapy or chemo-radiotherapy, respectively. In general, polymorphisms in the BER and NER pathways do not seem to play a relevant role in survival and response to treatment among never-smoker LC patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33273562</pmid><doi>10.1038/s41598-020-78051-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2020-12, Vol.10 (1), p.21147-21147, Article 21147
issn 2045-2322
2045-2322
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7713126
source Publicly Available Content Database; PubMed Central; Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access
subjects 692/4028
692/699
Adenocarcinoma
Aged
Case-Control Studies
Chemotherapy
Deoxyribonucleic acid
DNA
DNA Repair
ERCC1 protein
Female
Gene polymorphism
Humanities and Social Sciences
Humans
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Male
Middle Aged
multidisciplinary
Non-Smokers
OGG1 protein
Platinum
Polymorphism, Single Nucleotide
Radiation therapy
Science
Science (multidisciplinary)
Survival
Survival Analysis
Toxicity
title Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T22%3A15%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polymorphisms%20in%20the%20BER%20and%20NER%20pathways%20and%20their%20influence%20on%20survival%20and%20toxicity%20in%20never-smokers%20with%20lung%20cancer&rft.jtitle=Scientific%20reports&rft.au=Casal-Mouri%C3%B1o,%20Ana&rft.date=2020-12-03&rft.volume=10&rft.issue=1&rft.spage=21147&rft.epage=21147&rft.pages=21147-21147&rft.artnum=21147&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-78051-5&rft_dat=%3Cproquest_pubme%3E2473283867%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-2bf7c1509507248581285d1919bee60f2c6e80a792bfd4d025b8ff8d130d82a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2473283867&rft_id=info:pmid/33273562&rfr_iscdi=true